EXELLENS
LIVE

Serial Number

99422777

Owner

Samsung Biologics Co., Ltd.

Attorney

Brian P. Gregg

Filing Date

Oct 1, 2025

Add to watchlist:

No watchlists yet
View on USPTO

EXELLENS Trademark

Serial Number: 99422777

EXELLENS is a trademark filed by Samsung Biologics Co., Ltd. on October 1, 2025. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Samsung Biologics Co., Ltd. (26 trademarks)

300, Songdo bio-daero,

Entity Type: 03

Trademark Details

Filing Date

October 1, 2025

Registration Date

Not Registered

Goods & Services

business administration and office work; marketing services; demonstration of goods; import-export agency services; advertising services relating to pharmaceutical products; business advisory services for business in the field of medical services and healthcare; electronic data collection services for business purposes in the pharmaceutical and healthcare fields; providing consumer product information via the Internet; electronic data processing services relating to healthcare information; accounting consultancy services; healthcare cost management services; statistical analysis for research, development, and manufacturing in the field of biopharmaceuticals; data evaluation, and preparation of business reports in the field of biopharmaceutical research

conducting early evaluations in the field of new pharmaceuticals; drug discovery services; pharmaceutical research and development; research of pharmaceuticals; pharmaceutical product evaluation; scientific services, namely, toxicity analysis, cell-based toxicity assays, in vitro toxicity testing, bio-safety testing during drug development and manufacturing; scientific research services in the field of conducting clinical trials and supports for others; clinical studies of medicines; services for assessing the efficiency of pharmaceuticals, namely, potency and efficacy testing; analysis and evaluation of medical product development; medical research laboratory services; providing information on the testing, inspection and research of medical products; medicine research; evaluating of clinical trial progress being target group setting and data collection for scientific research purposes; computer programming services in the medical field; multiple nucleic acid analysis; scientific services being protein analysis for IPC, namely, release, stability testing, compendial testing, protein concentration, chemical/biochemical testing, protein characterization, and quantification; biotechnological research; genetic research, namely, gene expression analysis; scientific research; scientific molecular analysis services, namely, DNA and RNA analysis; research in the field of food; development in the field of biotechnology; biochemical analysis services; scientific research in the field of genetics and genetic engineering; biochemical research; cell culture services for scientific research purposes for others; biological analysis, namely, IPC (In-Process Control), release, and stability testing such as cell-based assays and binding ELISA (Enzyme-Linked Immunosorbent Assay), and biomarker analysis of biological samples; biological research; research of biologics; development of pharmaceutical preparations and medicines; scientific laboratory services for high-throughput glycan analysis; biological research and analysis relating to glycosylation profiling; technical support services for computer software in the nature of development and manufacturing process optimization/simulation, trend analysis, and risk management relating to handling of medical imaging data

Custom manufacture of biopharmaceuticals, processing of medicinal materials; preservation of pharmaceuticals; processing of pharmaceuticals; processing of chemicals; processing of biopharmaceutical materials for others; processing of biopharmaceutical products, namely, raw materials, cell culture, purification, and formulation services; chemical treatment of liquids; custom manufacturing of cell lines for biopharmaceutical production; custom manufacturing of glycosylated pharmaceutical preparations with specific antibody binding

Filing History

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 8, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 8, 2026 GNSL
SUSPENSION LETTER WRITTEN
Jun 8, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 12, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 12, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 21, 2026 GNRN
NON-FINAL ACTION E-MAILED
Feb 21, 2026 GNRT
NON-FINAL ACTION WRITTEN
Feb 21, 2026 CNRT
ASSIGNED TO EXAMINER
Feb 20, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 10, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Oct 1, 2025 MAFR
NEW APPLICATION ENTERED
Oct 1, 2025 NWAP